Levosimendan Kabi (Levosimendan)

Levosimendan is a calcium‑sensitizing inotrope used in the treatment of heart‑failure syndromes.

• Acute decompensated heart failure: improves cardiac output, reduces pulmonary congestion, and facilitates weaning from mechanical ventilation.
• Severe low‑output heart failure: increases myocardial contractility, enhances systemic perfusion, and may stabilize blood pressure in critically ill patients.
• Heart failure with reduced ejection fraction (selected patients): provides hemodynamic support as an adjunct to standard therapy when conventional inotropes are contraindicated or ineffective.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium without raising intracellular calcium levels, thereby enhancing myocardial contractility. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation. The combined inotropic and vasodilatory actions improve cardiac output while reducing preload and afterload, supporting overall significant circulatory stability in patients with compromised heart function.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypotension: transient reduction in blood pressure.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure drop requiring intervention.
• Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
• Anaphylactic reaction: rare allergic response with rash, swelling, or respiratory distress.

When using Levosimendan Kabi, several clinical precautions should be observed to ensure patient safety.

• Blood pressure monitoring: observe for hypotension during and after infusion.
• Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with pre‑existing conduction disorders.
• Renal impairment: adjust therapy cautiously in severe renal dysfunction.
• Hepatic dysfunction: use with care in patients with significant liver disease.
• Contraindication in severe hypotension: avoid administration if systolic blood pressure is below 90 mmHg.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, altering its hemodynamic effects or safety profile.

Major Interactions (Avoid)

• Sodium nitroprusside: combined vasodilation may cause profound hypotension.
• Other calcium‑sensitizing inotropes: additive effects increase risk of arrhythmias.
• Potent CYP3A4 inhibitors (e.g., ketoconazole): may raise levosimendan plasma concentrations.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic response.
• ACE inhibitors or ARBs: concurrent use can enhance hypotensive effect.
• Diuretics: volume depletion may exacerbate blood pressure fall.